Modified release formulations for oprozomib

US9295708B2 · kind B2 · utility

Assignee

• Onyx Therapeutics, Inc. · US

Inventors

• Mouhannad Jumaa · Foster City, US
• Tony Muchamuel · Ramona, US
• Naveen Bejugam · South San Francisco, US
• Hansen Wong · San Mateo, US
• Christopher J. Kirk · San Francisco, US
• Rahul Vishram Manek · Vallejo, US
• Sanjeev Sharma · San Diego, US

Key dates

• Filing date: Oct 24, 2013
• Grant date: Mar 29, 2016
• Expiry date: Oct 24, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure features modified release pharmaceutical formulations (e.g., extended release pharmaceutical formulations; e.g., solid dosage forms, e.g., tablets) that are useful for the oral administration of oprozomib, or a pharmaceutically acceptable salt thereof, to a human or animal subject as well as methods of making and using the formulations.